위선암종에서 p53 단백 및 CREB-결합 단백의 면역조직화학적 발현양상

다국어 초록 (Multilingual Abstract)

Purpose: The wild-type p53 protein participates in suppressing cell transformations while its mutant forms has tumorigenic potential. Alterations in the structure of the p53 protein are one of the most common changes associated with human cancers. CREB-binding protein (CBP) and its homologue, p300, are transcriptional co-activators of various sequence-specific DNA-binding transcription factors and are involved in a wide range of cellular activities, such as DNA repair, cell growth, differentiation, and apoptosis. Several studies suggested that an association between p53 and p300 might account for the p53-responsible negative regulation. This study examined the relationship between p53 and CBP expression in terms of the clinicopathological factors and significance.
Methods: The level of p53 protein and CBP expression was measured in 150 gastric adenocarcinoma patients, who had undergone a gastrectomy, and the relationship between p53 and CBP was examined. Immunohistochemical stain was performed on formalin-fixed paraffin-embedded sections using monoclonal anti-p53 and anti-CBP antibody.
Results: 1. p53 protein was expressed in 46.3% (31/67) of early gastric cancers (EGC), 69.9% (58/83) of advanced gastric cancers (AGC)(P＜0.05), 69.1% (65/94) of the intestinal type, 42.9% (24/56) of the diffuse type (P＜0.05), 78.5% (55/70) of patients with a lymph node metastasis and 42.5% (34/80) of patients without a lymph node metastasis (P＜0.01). 2. CBP expression was observed in 65% (61/94) of intestinal type, 51% (29/56) of the diffuse type (P＞0.05), 47.8% (32/67) of EGC, 69.8% (58/83) of AGC (P＜0.05), 68.6% (48/70) of patients with a lymph node metastasis and 52.5% (42/80) of patients without a lymph node metastasis (P＞0.05). 3. p53 protein and CBP expression was coincidentally observed in 66.7% of gastric adenocarcinomas, and there was a significant correlation between the expression of both (P＜0.05).
Conclusion: That the expression of the p53 protein and CBP indirectly indicate the malignant potential of a cell, and may play an indirect role in the CBP and p53-mediated tumorigenic potential.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• REFERENCES

참고문헌 (Reference)

1 Lane DP, "p53, guardian of the genome" 358 : 15-16, 1992

2 Hollstein M, "p53 mutations in human cancers" 253 : 49-53, 1991

3 Bosari S, "p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma" 147 : 790-798, 1995

4 Diller L, "p53 funtions as a cell cycle control protein in osteosarcoma" 10 : 5772-5783, 1990

5 Vogelstein B, "p53 function and dysfunction" 70 : 523-526, 1992

6 Ito A, "p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM-2" 20 : 1331-1340, 2001

7 Giordano A, "p300 and CBP, partners for life and death" 181 : 218-230, 1999

8 Yonish RE, "Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin" 352 : 345-352, 1991

9 Chang F, "Tumorigenesis associated with the p53 tumor suppressor gene" 68 : 653-661, 1993

10 Lauren P., "The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma" 64 : 31-49, 1965

11 Levine AJ, "The p53 tumor suppressor gene" 351 : 453-456, 1991

12 Lane DP, "T antigen is bound to a host protein in SV40 transformed cells" 278 : 261-263, 1979

13 Sasatomi E, "Spontaneous apoptosis in gallbladder carcinoma; relationships with clinicopathologic factors, expression of E-cadherin, Bcl-2 protooncogene, and p53 oncosuppressor gene" 78 : 2101-2110, 1996

14 Starzynska T, "Prognostic significance of p53 overexpression in gastric and colorectal carcinoma" 66 : 558-562, 1992

15 Lazaris AC, "Prognostic significance of p53 and C-erB2 immunohistochemical evaluation in colorectal adenocarcinoma" 10 : 661-668, 1995

16 Appella E, "Post-translational modifications and activation of p53 by genotoxic stresses" 268 : 2764-2772, 2001

17 Grossman SR., "P300/CBP/p53 interaction and regulation of the p53 response" 268 : 2773-2778, 2001

18 Tahara E, "Molecular biological observations in gastric cancer" 23 : 307-315, 1996

19 Kobet E, "MDM-2 inhibits p300-mediated p53 acetylation and activation by following a ternary complex with the two proteins" 97 : 12547-12552, 2000

20 Lavielle JP, "Immunohischemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck" 115 : 334-339, 1995

21 Munoz N, "Histologic types of gastric carcinoma in high- and low-risk areas" 3 : 809-818, 1968

22 Davessar K, "Gastric carcinoma: prognostic significance of several pathologic parameters and histologic classification" 21 : 325-332, 1990

23 Sakaguchi K, "DNA damage activates p53 through a phosphorylation-acetylation cascade" 12 : 2831-2841, 1998

24 Vo N, "CREB-binding protein and p300 in transcriptional regulation" 276 : 13505-13508, 2001

25 Goodman RH, "CBP/p300 in cell growth, transformation and development" 14 : 1553-1577, 2000

26 Gu W, "Activation of p53 sequence specific DNA- binding by acetylation of the C-terminal domain" 90 : 595-606, 1997

27 Bartek J, "Aberrant expression of the p53 oncoprotein in a common feature of a wide spectrum of human malignancies" 6 : 1699-1703, 1991

28 Zambetti GP, "A comparison of the biologic activities of wild type and mutant p53" 7 : 855-862, 1993